Albert David Ltd (ALBERTDAVD) AI Stock Analysis

• Market Cap: ₹3.77B
• Dividend Yield: 0.66%
• Average Volume (3M): 210.00
• Price to Earnings (P/E): 6.9
• Beta (1Y): 1.07
• Revenue Growth: -13.51%
• EPS Growth: -122.00%
• Country: IN
• Employees: 1,497
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 26.82
• Shares Outstanding: 5,707,162
• 10 Day Avg. Volume: 184
• 30 Day Avg. Volume: 210
• PEG Ratio: -0.36
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 1.37
• P/FCF Ratio: -10.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ₹664.00 ▼(-15.78% Downside)
• Action: Reiterated Date: 11/25/25
• Date: Action: Reiterated 11/25/25

Albert David Ltd's overall stock score is primarily impacted by its strong balance sheet, which is overshadowed by declining financial performance and bearish technical indicators. The negative P/E ratio and low dividend yield further weigh on the valuation.

Positive Factors

Balance Sheet Strength

Albert David's balance sheet exhibits low leverage and solid equity, providing financial stability and flexibility. This durable strength limits solvency risk, supports capital expenditure or working-capital financing needs without excessive borrowing, and underpins long-term resilience.

Gross Margin Profile

The company’s strong gross profit margin signals effective manufacturing and cost controls in its formulations business. Sustained gross margins provide a cushion against selling-pressure or input-cost swings, enabling reinvestment, targeted pricing strategies, and potential margin recovery at the net level over time.

Diversified Formulations Business

Albert David’s core business of branded and generic formulations sold across domestic channels and exports creates multiple revenue streams. This structural diversification across geographies and customer types supports resilience to local demand shocks and enables scale benefits in manufacturing and distribution.

Negative Factors

Falling Revenue

Revenue contraction of over 10% is a material structural concern as it reduces scale economics and puts pressure on margins and investment capacity. Persistent top-line decline undermines long-term growth prospects and raises questions about product demand, market share, or competitive positioning.

Weak Cash Generation

The shift to negative operating and free cash flow impairs the company’s ability to self-fund operations, R&D or capex. Over multiple quarters this stresses liquidity, may force external financing or asset sales, and limits strategic flexibility to invest in growth or defend market share.

Declining Net Profitability

A marked drop in net profit margin despite healthy gross margins indicates rising operating costs, lower pricing power, or one-off losses that hit the bottom line. Sustained margin compression reduces return on equity and cash available for dividends, investments, and debt servicing.

Albert David Ltd Business Overview & Revenue Model

Company Description

Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles in India. It offers formulations for parenterals, oral/enteral, topical agents, and vision care products. The company also exports its products to Latin American, Southeast Asian, and other African countries. The company was incorporated in 1938 and is headquartered in Kolkata, India.

How the Company Makes Money

The company makes money primarily by selling pharmaceutical formulations. Revenue is generated through (1) domestic sales to healthcare channels (such as distributors/stockists, pharmacies, and institutional customers) for branded and/or generic formulations, and (2) export sales of formulations to overseas customers/partners where applicable. Earnings are driven by product mix, volumes, pricing, tender/institutional orders (if any), and the scale and efficiency of its manufacturing and supply chain. Specific details on customer concentration, named partnerships, contract manufacturing arrangements, or the exact split between domestic and export revenues are null.

Albert David Ltd Financial Statement Overview

Summary

Albert David Ltd shows a strong balance sheet with low leverage and solid equity, but faces challenges with declining revenue, profitability, and negative cash flows. These issues need addressing for sustainable growth.

Income Statement

Albert David Ltd has shown a mixed performance in terms of revenue and profitability. The gross profit margin is strong, indicating effective cost management, but the net profit margin has declined significantly in the latest year, reflecting a decrease in profitability. Revenue has shown fluctuations, with a notable decline in the most recent year, which is a concern for growth prospects.

Balance Sheet

The company's balance sheet reflects solid equity and a low level of debt, which is a positive indicator of financial stability. The equity ratio is robust, and the company has maintained a strong return on equity, although it has decreased in the latest year. The low debt-to-equity ratio limits financial risk.

Cash Flow

Cash flow from operations has turned negative in the latest year, which is a significant drawback. Free cash flow also fell into negative territory, indicating potential liquidity issues. In previous years, cash flow metrics were healthier, but the recent downturn in free cash flow growth rate raises concerns about the company's ability to generate cash.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.16B	3.46B	3.60B	3.42B	3.12B	2.46B
Gross Profit	1.75B	2.29B	2.32B	2.18B	1.95B	1.58B
EBITDA	-359.98M	30.26M	1.05B	598.68M	567.76M	364.59M
Net Income	-150.80M	172.01M	754.20M	361.75M	352.58M	221.43M
Balance Sheet
Total Assets	5.33B	5.11B	4.98B	4.23B	4.03B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.84B	2.44B	2.85B	2.03B	1.75B	1.49B
Total Debt	414.14M	123.17M	33.24M	53.18M	56.62M	16.19M
Total Liabilities	1.39B	1.19B	1.15B	1.12B	1.23B	970.20M
Stockholders Equity	3.94B	3.92B	3.83B	3.12B	2.79B	2.44B
Cash Flow
Free Cash Flow	-271.21M	-432.92M	346.28M	52.78M	292.83M	349.79M
Operating Cash Flow	-208.45M	-284.36M	455.02M	105.15M	403.65M	366.11M
Investing Cash Flow	-46.97M	233.01M	-332.48M	-49.95M	-396.97M	-366.84M
Financing Cash Flow	248.82M	1.10M	-82.70M	-63.62M	-12.59M	-17.05M

Albert David Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 788.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 788.4 is above the 20-day moving average (MA) of 686.73, above the 50-day MA of 700.57, and below the 200-day MA of 789.48, indicating a bearish trend. The MACD of -11.98 indicates Positive momentum. The RSI at 38.85 is Neutral, neither overbought nor oversold. The STOCH value of 62.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.

Albert David Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZIMLAB	63 Neutral	₹3.34B	19.99	―	―	-5.82%	-59.22%
LYKALABS	54 Neutral	₹1.97B	-338,564.26	―	―	4.04%	-35.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALBERTDAVD	51 Neutral	₹3.77B	6.87	―	0.66%	-13.51%	-122.00%
VIKASLIFE	48 Neutral	₹2.40B	-32.50	―	―	9.42%	-12220.00%
BROOKS	46 Neutral	₹1.55B	10.71	―	―	18.67%	―
NECLIFE	46 Neutral	₹2.45B	7.63	―	―	-30.27%	-3470.06%

Albert David Ltd Corporate Events

Albert David Publishes Notice on Re-Lodgement of 300 Physical Shares

Albert David Ltd has disclosed that it received a request from investor Bharat Kumar N Jain for transfer of 300 physical equity shares into his name, relating to securities previously purchased but not transferred. In line with SEBI guidelines on transfer of physical securities, the company has invited any counterclaims from potential claimants within 30 days, after which it will proceed with the transfer if no valid objections are received.

To comply with regulatory requirements and ensure transparency, Albert David has published details of this re-lodgement of share transfer in the March 13, 2026 editions of Financial Express and Aajkal. The move underscores the company’s adherence to SEBI’s investor protection framework and formalizes the process for resolving ownership of legacy physical share certificates before completing the transfer to the requesting investor.

Albert David to Close Trading Window Ahead of Q3 FY2025-26 Results

Albert David Limited has announced that its trading window for dealing in the company’s shares will be closed from 1 January 2026 in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct on insider trading. During this period, designated persons, insiders and their immediate relatives are barred from trading in the company’s securities, with additional controls including PAN-level freezing of designated persons’ accounts via CDSL, until 48 hours after the release of its unaudited financial results for the third quarter and nine months ended 31 December 2025; the board meeting date to consider these results will be announced separately.